Comprehensive in Vivo and in Vitro Platform for Evaluating Drug Efficacy Against Cancer Cells in Patient Treatment

This research presents a pioneering approach to personalized breast cancer treatment, emphasizing the importance of individualized therapeutic strategies. Leveraging a microfluidic platform, impedance analysis, and Matrigel encapsulation, tissue samples from three distinct breast cancer patients were comprehensively assessed to determine the most effective drug for each individual. Impedance values, serving as quantitative markers of cellular behaviour, revealed distinct drug responsiveness patterns, thus highlighting the need for tailored treatment approaches. Tucatinib exhibited remarkable efficacy for Person 1, while Sacituzumab Govitecan emerged as the optimal choice for Persons 2 and 3. The study's methodology, replicating the tumor microenvironment in vitro through Matrigel, enhances the physiological relevance of the findings. Although limitations, including a small sample size, necessitate further validation in larger cohorts, the potential for enhancing breast cancer treatment outcomes is unmistakable. Future research could integrate additional patient-specific factors to refine personalized treatment recommendations. In summary, this research signifies a significant stride towards precision medicine in breast cancer therapy, aiming to improve patient outcomes by tailoring treatments to the unique characteristics of each patient's cancer.